Serge Boveda1, Andreas Metzner2, Dinh Q Nguyen3, K R Julian Chun4, Konrad Goehl5, Georg Noelker6, Jean-Claude Deharo7, George Andrikopoulos8, Tillman Dahme9, Nicolas Lellouche10, Pascal Defaye11. 1. Clinique Pasteur, Toulouse, France. Electronic address: sboveda@clinique-pasteur.com. 2. Asklepios Klinik St. Georg, Hamburg, Germany. 3. St. Vinzenz-Hospital, Köln, Germany. 4. Markuskrankenhaus, Cardioangiologisches Centrum Bethanien, Frankfurt, Germany. 5. Klinikum Nürnberg Süd, Nürnberg, Germany. 6. Clinic for Cardiology Herz- und Diabeteszentrum North Rhine-Westphalia Ruhr-Universität Bochum, Bad Oeynhausen, Germany. 7. Centre Hospitalier Universitaire de la Timone, Marseille, France. 8. Henry Dunant Hospital Center, Athens, Greece. 9. Universitätsklinikum Ulm, Ulm, Germany. 10. Centre Hospitalier Universitaire Henri Mondor, Créteil, France. 11. Centre Hospitalier Universitaire de Grenoble-Alpes, Grenoble, France.
Abstract
OBJECTIVES: The CRYO4PERSISTENT AF (Cryoballoon Ablation for Early Persistent Atrial Fibrillation) trial aims to report long-term outcomes after a single pulmonary vein isolation (PVI)-only ablation procedure using the second-generation cryoballoon in persistent atrial fibrillation (PerAF) patients. BACKGROUND: Pulmonary vein isolation is recognized as the cornerstone of atrial fibrillation (AF) ablation, including ablation of PerAF. METHODS: The CRYO4PERSISTENT AF trial (NCT02213731) is a prospective, multicenter, single-arm trial designed to assess single-procedure outcomes of PVI using the cryoballoon. The primary endpoint was freedom from AF, atrial flutter, or atrial tachycardia ≥30 s after a 90-day blanking period. After enrollment, but before ablation, patients without 100% AF burden (18-h Holter monitoring or 3 consecutive electrocardiograms in a time frame ≥14 days) were excluded. Patients were followed at 3, 6, and 12 months, with 48-h Holter monitoring at 6 and 12 months. Quality of life and symptoms were evaluated at baseline and 12 months. Arrhythmia recurrence and adverse events were adjudicated by an independent committee. RESULTS: A total of 101 patients (62 ± 11 years of age, 74% men, left ventricular ejection fraction 56 ± 8%, left atrial diameter 43 ± 5 mm) meeting criteria, undergoing cryoballoon-based PVI, with follow-up data, were included. Kaplan-Meier estimate of freedom from AF, atrial flutter, or atrial tachycardia recurrence was 60.7% at 12 months. Compared with baseline, there were significantly fewer patients with arrhythmia-related symptoms at 12 months (16% vs. 92%; p < 0.0001). The symptom reduction was supported by significant improvement in 36-Item Short Form Health Survey composite scores and European Heart Rhythm Association score at 12 months. The only device related event was transient phrenic nerve injury in 2 (2%) patients, with resolution pre-discharge. CONCLUSIONS:Cryoballoon ablation for treatment of PerAF demonstrated 61% single-procedure success at 12 months post-ablation in addition to significant reduction in arrhythmia-related symptoms and improved quality of life. (Cryoballoon Ablation for Early Persistent Atrial Fibrillation [Cryo4 Persistent AF]; NCT02213731).
RCT Entities:
OBJECTIVES: The CRYO4PERSISTENT AF (Cryoballoon Ablation for Early Persistent Atrial Fibrillation) trial aims to report long-term outcomes after a single pulmonary vein isolation (PVI)-only ablation procedure using the second-generation cryoballoon in persistent atrial fibrillation (PerAF) patients. BACKGROUND: Pulmonary vein isolation is recognized as the cornerstone of atrial fibrillation (AF) ablation, including ablation of PerAF. METHODS: The CRYO4PERSISTENT AF trial (NCT02213731) is a prospective, multicenter, single-arm trial designed to assess single-procedure outcomes of PVI using the cryoballoon. The primary endpoint was freedom from AF, atrial flutter, or atrial tachycardia ≥30 s after a 90-day blanking period. After enrollment, but before ablation, patients without 100% AF burden (18-h Holter monitoring or 3 consecutive electrocardiograms in a time frame ≥14 days) were excluded. Patients were followed at 3, 6, and 12 months, with 48-h Holter monitoring at 6 and 12 months. Quality of life and symptoms were evaluated at baseline and 12 months. Arrhythmia recurrence and adverse events were adjudicated by an independent committee. RESULTS: A total of 101 patients (62 ± 11 years of age, 74% men, left ventricular ejection fraction 56 ± 8%, left atrial diameter 43 ± 5 mm) meeting criteria, undergoing cryoballoon-based PVI, with follow-up data, were included. Kaplan-Meier estimate of freedom from AF, atrial flutter, or atrial tachycardia recurrence was 60.7% at 12 months. Compared with baseline, there were significantly fewer patients with arrhythmia-related symptoms at 12 months (16% vs. 92%; p < 0.0001). The symptom reduction was supported by significant improvement in 36-Item Short Form Health Survey composite scores and European Heart Rhythm Association score at 12 months. The only device related event was transient phrenic nerve injury in 2 (2%) patients, with resolution pre-discharge. CONCLUSIONS: Cryoballoon ablation for treatment of PerAF demonstrated 61% single-procedure success at 12 months post-ablation in addition to significant reduction in arrhythmia-related symptoms and improved quality of life. (Cryoballoon Ablation for Early Persistent Atrial Fibrillation [Cryo4 Persistent AF]; NCT02213731).
Authors: Federico Cecchini; Giacomo Mugnai; Saverio Iacopino; Juan Pablo Abugattas; Bert Adriaenssens; Maysam Al-Housari; Alexandre Almorad; Gezim Bala; Antonio Bisignani; Carlo de Asmundis; Yves De Greef; Riccardo Maj; Thiago G Osòrio; Luigi Pannone; Bruno Schwagten; Juan Sieira; Antonio Sorgente; Erwin Stroker; Michael Wolf; Gian-Battista Chierchia Journal: J Interv Card Electrophysiol Date: 2022-07-22 Impact factor: 1.759
Authors: Omar Anwar; Melanie A Gunawardene; Jannis Dickow; Katharina Scherschel; Christiane Jungen; Paula Münkler; Christian Eickholt; Stephan Willems; Nele Gessler; Christian Meyer Journal: PLoS One Date: 2020-06-25 Impact factor: 3.240
Authors: Ikechukwu Ifedili; Kristina Mouksian; David Jones; Ibrahim El Masri; Mark Heckle; John Jefferies; Yehoshua C Levine Journal: Curr Cardiol Rev Date: 2022
Authors: Graham Peigh; Jeremiah Wasserlauf; Rachel M Kaplan; Ansel P Amaral; Amar Trivedi; Alexandru B Chicos; Rishi Arora; Susan Kim; Albert Lin; Nishant Verma; Bradley P Knight; Rod S Passman Journal: J Cardiovasc Electrophysiol Date: 2020-03-09 Impact factor: 2.942
Authors: Laura Rottner; Barbara Bellmann; Tina Lin; Bruno Reissmann; Tobias Tönnis; Ruben Schleberger; Moritz Nies; Christiane Jungen; Leon Dinshaw; Niklas Klatt; Jannis Dickow; Paula Münkler; Christian Meyer; Andreas Metzner; Andreas Rillig Journal: Cardiol Ther Date: 2020-01-02
Authors: Gaëlle Vermeersch; Juan-Pablo Abugattas; Varnavas Varnavas; Jeroen De Cocker; Bruno Schwagten; Juan Sieira; Carlo de Asmundis; Gian-Battista Chierchia; Yves De Greef Journal: J Arrhythm Date: 2021-03-26